TY - JOUR
T1 - Efficacy of olanzapine and risperidone in schizophrenia
T2 - a randomized double-blind crossover design.
AU - Canive, Jose M.
AU - Miller, Gregory A.
AU - Irwin, Jessica G.
AU - Moses, Sandra N.
AU - Thoma, Robert J.
AU - Edgar, J. Christopher
AU - Sherwood, Andrea
AU - Torres, Fernando
AU - Lanoue, Marianna
AU - Lewis, Stephen
AU - Hanlon, Faith M.
AU - Weisend, Michael P.
AU - Mead, Valerie
AU - Tuason, Vicente B.
PY - 2006
Y1 - 2006
N2 - This article compares the efficacy of olanzapine and risperidone for positive and negative symptoms using an 18-week, randomized, double-blind, crossover design. The hypotheses were that olanzapine would be more efficacious for treating negative symptoms, and that risperidone would be superior in treating positive symptoms. Positive and negative symptoms scores improved throughout treatment, regardless of medication type. Differences between the medications were found for negative and general psychopathology rating scales. Overall, olanzapine led to greater improvements in negative symptoms than did risperidone. When each scale was analyzed individually, greater improvements were found for olanzapine on Positive and Negative Symptoms Scale (PANSS) General,PANSS total, and Scale for the Assessment of Negative Symptoms (SANS)attention. A nearly significant trend favoring olanzapine was found for the Calgary Depression Scale. Several negative symptom subscales followed a nonsignificant trend toward olanzapine being more efficacious than risperidone.Thus, there was a very consistent pattern of greater efficacy for olanzapine, particularly for negative symptoms. Despite the small number of subjects, this study shows the potential of a within-subject design to elucidate differences in efficacy.
AB - This article compares the efficacy of olanzapine and risperidone for positive and negative symptoms using an 18-week, randomized, double-blind, crossover design. The hypotheses were that olanzapine would be more efficacious for treating negative symptoms, and that risperidone would be superior in treating positive symptoms. Positive and negative symptoms scores improved throughout treatment, regardless of medication type. Differences between the medications were found for negative and general psychopathology rating scales. Overall, olanzapine led to greater improvements in negative symptoms than did risperidone. When each scale was analyzed individually, greater improvements were found for olanzapine on Positive and Negative Symptoms Scale (PANSS) General,PANSS total, and Scale for the Assessment of Negative Symptoms (SANS)attention. A nearly significant trend favoring olanzapine was found for the Calgary Depression Scale. Several negative symptom subscales followed a nonsignificant trend toward olanzapine being more efficacious than risperidone.Thus, there was a very consistent pattern of greater efficacy for olanzapine, particularly for negative symptoms. Despite the small number of subjects, this study shows the potential of a within-subject design to elucidate differences in efficacy.
UR - http://www.scopus.com/inward/record.url?scp=39049174070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39049174070&partnerID=8YFLogxK
M3 - Article
C2 - 17065975
AN - SCOPUS:39049174070
SN - 0048-5764
VL - 39
SP - 105
EP - 116
JO - Psychopharmacology bulletin
JF - Psychopharmacology bulletin
IS - 1
ER -